Page 3 - Biocon Stock

Biocon shares gain 4% after USFDA gives VAI tag to its Malaysia unit

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru facility in Malaysia was classified as "Voluntary Action Indicated"

Biocon rises 3% after its arm gets US FDA nod for psoriasis drug YESINTEK

Biocon Biologics Ltd had previously notified on February 29, 2024, that the company had entered into a settlement and licensing agreement with Janssen

Biocon share jumps 6% on USFDA's 'VAI' tag to Bengaluru facility; details

The surge in Biocon share price came after the company announced that United States Food and Drug Administration (USFDA) has classified Biocon Biologics' Biocon Park Site in Bengaluru as VAI

Biocon shares tank 6% after reporting net loss of Rs 16 cr in Q2FY25

Shares of pharmaceutical company Biocon tanked 5.96 per cent at Rs 301.65 a piece on the BSE

Stocks to Watch, Oct 31: Biocon, L&T, Tata Power, RVNL, Zydus Wellness

Stocks to Watch, October 31, 2024: L&T's revenue up 20.63 per cent at Rs 61,554 crore versus Rs 51,024 crore. Ebitda up 12.94 per cent at Rs 6,362 crore versus Rs 5,633 crore

Biocon Q2 FY25 results: Net profit declines 84% to Rs 27.1 crore

Revenue driven by gains from US Oncology and Insulins franchises

Biocon, PFC, Chambal Fert; top picks by Ajit Mishra of Religare Broking

The pharma sector is showing notable resilience, with Biocon taking the lead. The stock has broken out from a bullish rectangle pattern, accompanied by a strong surge in volumes

Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure

Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure. Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The medicine is also used to treat paediatric patients over the age of one year. The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.

Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24

Adani Ports, Zydus Life, Paytm, Zomato among 11 stocks to track on June 18

On the previous day, US markets settled higher, with Nasdaq and S&P 500 reaching record highs

Stocks to watch on June 04: DRL, Biocon, Wipro, RVNL, M&M Fin Svcs

Stocks to watch on June 04: RVNL has secured an engineering, procurement and construction order worth Rs 440 crore from South Central Railway

Biocon signs licensing, supply deal for obesity drug in South Korea

Bengaluru-based company announces 'strategic partnership' with Handok

Stocks to Watch, May 22: Apollo Tyres, Biocon, Gulf Oil, Ircon Int'l

European markets closed on a negative note, with Germany's DAX falling 0.22 per cent and the UK's FTSE dropping 0.09 per cent

RIL, Adani Ports, Vi, Biocon, CONCOR among nine stocks to track on May 17

At 6:51 AM, GIFT Nifty futures showed a rise of 26 points, trading at 22,478 levels, signaling a subdued start for the stock exchanges

Biocon receives a penalty of over Rs 3 crore in GST related issues

Biocon Ltd on Friday said it has been imposed a penalty of over Rs 3 crore over GST-related issues. The company has received an order of adjudication imposing a penalty of Rs 3,03,78,465 dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore, Biocon Ltd said in a regulatory filing. The demand is related to input tax credit reporting error in GST monthly returns, denial of input tax credit on sales and promotional expenditures, valuation issue GST under corporate guarantee, and denial of exemption on export of services, it added. Biocon further said it is "in the process of taking appropriate actions, including but not limited to, filing of the necessary appeal with the appellate authority in this regard". There is no material impact on the financials, operations or other activities of the company, the filing said.

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

Investing half a billion dollar in our generics business: Biocon MD & CEO

Debt-reduction plans are progressing a tad slowly, said Siddharth Mittal

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

Biocon Biologics appoints Kedar Upadhye as new chief financial officer

Current CFO, MB Chinappa will take on a strategic finance role at Biocon Group